drugset / Trial / NCT00301730

Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung

NCT00301730

Phase 1 Completed 1 enrolled National Cancer Institute (NCI)
Treatment

Summary

RATIONALE: Biological therapy, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying how well cellular adoptive immunotherapy works in treating a patient who has undergone a donor stem cell transplant for breast cancer that has spread to the lung.

Timeline

Start
2005-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy Intravenous
Background Paclitaxel Small molecule Intravenous
Background Trastuzumab Monoclonal antibody Intravenous
Background aldesleukin Protein / enzyme biologic Subcutaneous